menu
    • menu
    [{"orgOrder":0,"company":"Biolab Sanus Farmaceutica Ltda","sponsor":"George Medicines","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Telmisartan","moa":"||Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Biolab Sanus Farmaceutica Ltda","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Biolab Sanus Farmaceutica Ltda \/ Biolab Sanus Farmaceutica Ltda","highestDevelopmentStatusID":"15","companyTruncated":"Biolab Sanus Farmaceutica Ltda \/ Biolab Sanus Farmaceutica Ltda"}]

    Find Clinical Drug Pipeline Developments & Deals by Biolab Sanus Farmaceutica Ltda

    Menu

    Biolab Sanus Farmaceutica Ltda

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biolab Sanus Farmaceutica Ltda

                            Brazil arrow
                            AAPS
                            Not Confirmed

                            Biolab Sanus Farmaceutica Ltda

                            Brazil arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Recipient : George Medicines

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            George Medicines strengthens global commercialization strategy for GMRx2

                            Details : Biolab Farmacêutica gains exclusive rights in Brazil to GMRx2, an innovative single pill combination of three medicines, telmisartan, amlodipine and indapamide, for the treatment of hypertension.

                            Product Name : GMRx2

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 02, 2025

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Recipient : George Medicines

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth